Outlook Therapeutics (OTLK) Current Leases (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Current Leases of $62003.0 for Q1 2026, up 13.92% year-over-year from $54425.0 in Q1 2025, and up 1.44% quarter-over-quarter from $61125.0 in Q4 2025.
Outlook Therapeutics (OTLK) Current Leases (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Current Leases for 12 consecutive years, with $62003.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 13.92% year-over-year to $62003.0; the TTM figure through Mar 2026 stood at $62003.0 (up 13.92% YoY), while the FY2025 annual figure was $58897.0, up 15.7% from the prior year.
- Current Leases advanced to $62003.0 in Q1 2026 per OTLK's latest filing, from $61125.0 in the prior quarter.
- Across five years, Current Leases topped out at $62003.0 in Q1 2026 and bottomed at $1084.0 in Q4 2023.
- Historically, Current Leases has averaged $31568.2 across 5 years, with a median of $25111.5 in 2022.
- Annual changes were most pronounced in 2023 — Current Leases tumbled 93.04% — and 2024, when it surged 4756.55%.
- Outlook Therapeutics' Current Leases stood at $15573.0 in 2022, then sank by 93.04% to $1084.0 in 2023, then soared by 4756.55% to $52645.0 in 2024, then advanced by 16.11% to $61125.0 in 2025, then rose by 1.44% to $62003.0 in 2026.
- Business Quant data shows OTLK's Current Leases at $62003.0 in Q1 2026, $61125.0 in Q4 2025, and $58897.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | - |
| 10 | Outlook Therapeutics | 93.34 Mn | 82.10 Mn | -8,265.00 | 64,016.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,003.00 |
| Dec 31, 2025 | 61,125.00 |
| Sep 30, 2025 | 58,897.00 |
| Jun 30, 2025 | 56,560.00 |
| Mar 31, 2025 | 54,425.00 |
| Dec 31, 2024 | 52,645.00 |
| Sep 30, 2024 | 50,907.00 |
| Jun 30, 2024 | 31,801.00 |
| Dec 31, 2023 | 1,084.00 |
| Sep 30, 2023 | 4,267.00 |
| Jun 30, 2023 | 7,349.00 |
| Mar 31, 2023 | 3,929.00 |
| Dec 31, 2022 | 15,573.00 |
| Sep 30, 2022 | 11,751.00 |
| Jun 30, 2022 | 14,354.00 |
| Mar 31, 2022 | 18,422.00 |
| Dec 31, 2021 | 22,460.00 |
| Sep 30, 2021 | 26,464.00 |
| Jun 30, 2021 | 41,720.00 |
| Mar 31, 2021 | 26,972.00 |